Activation of mTOR Ameliorates Fragile X Premutation rCGG Repeat-Mediated Neurodegeneration

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Lin, Yunting ^a   Tang, Chengyuan ^a   He, Hua ^a   Duan, Ranhui ^a  

^a Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RILMENIDINE; FMR1 PROTEIN, HUMAN; FRAGILE X MENTAL RETARDATION PROTEIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CAG REPEAT; CONTROLLED STUDY; DROSOPHILA; DRUG ACTIVITY; ENZYME ACTIVATION; FMR1 GENE; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; GENE EXPRESSION; GENE TARGETING; IMMUNOSUPPRESSIVE TREATMENT; MUTATIONAL ANALYSIS; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFECTS; FRAGILE X SYNDROME; GENETICS; HUMAN; METABOLISM; TRINUCLEOTIDE REPEAT;

ANIMALIA; MAMMALIA;

ANIMALS; AUTOPHAGY; DISEASE MODELS, ANIMAL; DROSOPHILA; ENZYME ACTIVATION; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; NEURODEGENERATIVE DISEASES; PHENOTYPE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84876559854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062572     Document Type: Article

References (49)

1. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, et al. (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 57: 127-130.
2. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, et al. (2003) Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 72: 869-878.
3. Dombrowski C, Lévesque S, Morel ML, Rouillard P, Morgan K, et al. (2002) Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 11: 371-378.
4. Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, et al. (2003) RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 39: 739-747.
5. Berman RF, Willemsen R, (2009) Mouse models of fragile X-associated tremor ataxia. J Investig Med 57: 837-841.
6. Van Dam D, Errijgers V, Kooy RF, Willemsen R, Mientjes E, et al. (2005) Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res 162: 233-239.
7. Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen LA, et al. (2003) The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 12: 949-959.
8. Brouwer JR, Huizer K, Severijnen LA, Hukema RK, Berman RF, et al. (2008) CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 107: 1671-1682.
9. Bové J, Martínez-Vicente M, Vila M, (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 12: 437-452.
10. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585-595.
11. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, et al. (2010) Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 133: 93-104.
12. Montie HL, Cho MS, Holder L, Liu Y, Tsvetkov AS, et al. (2009) Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 18: 1937-1950.
13. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, et al. (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease. PLoS One 5: e9979.
14. Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rubinsztein DC, (2006) Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 15: 1209-1216.
15. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S, (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-β, and Tau: effects on cognitive impairments. J Biol Chem 285: 13107-13120.
16. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, et al. (2010) Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 11: 35-46.
17. Beffy P, Del Carratore R, Masini M, Furling D, Puymirat J, et al. (2010) Altered signal transduction pathways and induction of autophagy in human myotonic dystrophy type 1 myoblasts. Int J Biochem Cell Biol 42: 1973-1983.
18. Domanskyi A, Geissler C, Vinnikov IA, Alter H, Schober A, et al. (2011) Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J 25: 2898-2910.
19. Rieker C, Engblom D, Kreiner G, Domanskyi A, Schober A, et al. (2011) Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling. J Neurosci 31: 453-460.
20. Sarkar S, Krishna G, Imarisio S, SaikiS, O'Kane CJ, et al. (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17: 170-178.
21. Moskalev AA, Shaposhnikov MV, (2010) Pharmacological inhibition of phosphoinositide 3 and TOR kinases improves survival of Drosophila melanogaster. Rejuvenation Res 13: 246-247.
22. Rose C, Menzies FM, Renna M, Acevedo-Arozena A, Corrochano S, et al. (2010) Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet 19: 2144-2153.
23. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, et al. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460: 392-395.
24. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA, (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 30: 1166-1175.
25. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC, (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 16: 46-56.
26. Majumder S, Richardson A, Strong R, Oddo S, (2011) Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 6: e25416.
27. Banerjee R, Beal MF, Thomas B, (2010) Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci 33: 541-549.
28. Todd PK, Oh SY, Krans A, Pandey UB, Di Prospero NA, et al. (2010) Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet 6: e1001240.
29. Lu C, Lin L, Tan H, Wu H, Sherman SL, et al. (2012) Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice. Hum Mol Genet 21: 5039-5047.
30. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, et al. (2002) Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 125: 1760-1771.
31. Tassone F, Iwahashi C, Hagerman PJ, (2004) FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 1: 103-105.
32. Iwahashi CK, Yasui DH, An HJ, Greco CM, Tassone F, et al. (2006) Protein composition of the intranuclear inclusions of FXTAS. Brain 129: 256-271.
33. Jin P, Duan R, Qurashi A, Qin Y, Tian D, et al. (2007) Pur α binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 55: 556-564.
34. Sofola OA, Jin P, Qin Y, Duan R, Liu H, et al. (2007) RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 55: 565-571.
35. Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, et al. (2009) Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 29: 6367-6378.
36. Narayanan SP, Flores AI, Wang F, Macklin WB, (2009) Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 29: 6860-6870.
37. Gomez O, Sanchez-Rodriguez A, Le M, Sanchez-Caro C, Molina-Holgado F, et al. (2011) Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. Br J Pharmacol 163: 1520-1532.
38. Lian H, Ma Y, Feng J, Dong W, Yang Q, et al. (2012) Heparin-binding EGF-like growth factor induces heart interstitial fibrosis via an Akt/mTor/p70s6k pathway. PLoS One 7: e44946.
39. Chang HY, Kao MC, Way TD, Ho CT, Fu E, (2011) Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin. J Agric Food Chem 59: 5357-5363.
40. Lian N, Lin T, Liu W, Wang W, Li L, et al. (2012) Transforming growth factor β suppresses osteoblast differentiation via the vimentin activating transcription factor 4 (ATF4) axis. J Biol Chem 287: 35975-35984.
41. Hung CM, Kuo DH, Chou CH, Su YC, Ho CT, et al. (2011) Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells. J Agric Food Chem 59: 9683-9690.
42. Kuo SZ, Blair KJ, Rahimy E, Kiang A, Abhold E, et al. (2012) Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer 12: 556.
43. Sun Q, Chen X, Ma J, Peng H, Wang F, et al. (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 108: 4129-4134.
44. Onda H, Crino PB, Zhang H, Murphey RD, Rastelli L, et al. (2002) Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci 21: 561-574.
45. Chou SD, Prince T, Gong J, Calderwood SK, (2012) mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis. PLoS One 7: e39679.
46. Yan H, Frost P, Shi Y, Hoang B, Sharma S, et al. (2006) Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 66: 2305-2313.
47. Wang YH, Li YC, Huo SJ, Yin ZQ, (2012) α-crystallin promotes rat olfactory ensheathing cells survival and proliferation through regulation of PI3K/Akt/mTOR signaling pathways. Neurosci Lett 531: 170-175.
48. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, et al. (2007) HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447: 859-863.
49. Qurashi A, Liu H, Ray L, Nelson DL, Duan R, et al. (2012) Chemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila. Hum Mol Genet 21: 2068-2075.